Windtree Therapeutics Inc (WINT) USD0.001

Sell:$0.87Buy:$0.87$0.16 (20.68%)

Prices delayed by at least 15 minutes
Sell:$0.87
Buy:$0.87
Change:$0.16 (20.68%)
Prices delayed by at least 15 minutes
Sell:$0.87
Buy:$0.87
Change:$0.16 (20.68%)
Prices delayed by at least 15 minutes

Company Information

About this company

Windtree Therapeutics, Inc. is a diversified company. The Company is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The Company also has a licensing business model with partnership out-licenses in place. The Company is also focused on environmental services space.

Key people

Jed Latkin
President, Chief Executive Officer, Director
Eric L. Curtis
Chief Operating Officer, Senior Vice President
Diane Carman
Senior Vice President, General Counsel, Corporate Secretary
Steven G. Simonson
Senior Vice President, Chief Medical Officer
Mark Strobeck
Lead Independent Director
Leanne M. Kelly
Independent Director
Saundra Pelletier
Independent Director
Robert Scott
Independent Director
Click to see more

Key facts

  • EPIC
    WINT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US97382D6004
  • Market cap
    $2.82m
  • Employees
    14
  • Shares in issue
    3.66m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.